SCHEMBL29820165

SCHEMBL29820165

CC(C)c1ccc(C(N[S+]([O-])C(C)(C)C)c2cccnc2NC(=O)OC(C)(C)C)cc1F

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.35
ALDH1A1 P00352 1/20 0.35
FAAH O00519 1/20 0.34
S1PR3 Q99500 2/20 0.34
P2RY1 P47900 1/20 0.34
TRPM8 Q7Z2W7 2/20 0.33
MAPK1 P28482 1/20 0.33
SYK P43405 1/20 0.33
METAP1 P53582 1/20 0.32
NPC1 O15118 1/20 0.32
HSP90AA1 P07900 1/20 0.32
RAB9A P51151 1/20 0.32
PAX8 Q06710 1/20 0.32
CYP3A4 P08684 1/20 0.31
CYP3A5 P20815 1/20 0.31
AAK1 Q2M2I8 2/20 0.31
P2RX3 P56373 1/20 0.31
CYP17A1 P05093 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24666066 1.00 L3MBTL1 (0.35) L3MBTL1ALDH1A1FAAHS1PR3P2RY1
SCHEMBL29820164 0.83 P2RY1 (0.39) L3MBTL1ALDH1A1FAAHS1PR3P2RY1
SCHEMBL24666063 0.83 P2RY1 (0.39) L3MBTL1ALDH1A1FAAHS1PR3P2RY1
SCHEMBL29820461 0.78 HTRA1 (0.38) S1PR3CYP3A4CYP3A5
SCHEMBL24666068 0.78 HTRA1 (0.38) S1PR3CYP3A4CYP3A5
SCHEMBL20901331 0.77 METAP1 (0.44) L3MBTL1ALDH1A1P2RY1MAPK1SYK
SCHEMBL27350493 0.74 ALDH1A1 (0.34) ALDH1A1CYP3A4
SCHEMBL32664850 0.74 ALDH1A1 (0.34) ALDH1A1CYP3A4
SCHEMBL30816994 0.73 KDM4E (0.38) ALDH1A1S1PR3HSP90AA1
SCHEMBL30816992 0.73 KDM4E (0.38) ALDH1A1S1PR3HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534453-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2026-01-27 US disclosed
US-20240246939-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-07-25 US disclosed
EP-4308095-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2024-01-24 EP disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
US-20230104740-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2023-04-06 US disclosed
WO-2022198196-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL L3MBTL1 1532/4885ALDH1A1 2458/4885FAAH 4807/4885
US-20230104740-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF GYS2, GYS1, PYGL L3MBTL1 1532/4885ALDH1A1 2458/4885FAAH 4807/4885
US-12534453-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS1, GYS2, GBA1 L3MBTL1 656/4885ALDH1A1 2276/4885FAAH 3541/4885
US-20240246939-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF GYS2, GYS1, PYGL L3MBTL1 1532/4885ALDH1A1 2458/4885FAAH 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.